Novartis Reports Positive ALIGN Phase III Results for Vanrafia in IgA Nephropathy (NVAS)

Novartis (NVAS) announced positive top-line results from the Phase III ALIGN study evaluating Vanrafia in patients with IgA nephropathy. The trial met primary endpoints, with significant reductions in proteinuria observed, supporting the drug’s potential to slow disease progression. Secondary endpoints showed improvements in renal function and fewer treatment interruptions. The company plans to submit a New Drug Application in the first half of 2026.